Amgen Victorious in TKT Patent Litigation
BusinessWire
Friday January 19 7:26pm
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Jan. 19, 2001--Amgen (NASDAQ:AMGN) today announced that judgment was entered in its favor in the patent litigation against TKT and Aventis relating to erythropoietin.
Judge William G. Young of the U.S. District Court of Massachusetts ruled that three of Amgen's patents, U.S. Patent Nos. 5,621,080, 5,756,349 and 5,955,422 were held valid and infringed by TKT's GA-EPO product. The court also held that one patent, 5,547,933, was not infringed. As previously announced, the court held during trial that a fifth patent, 5,618,698, was also not infringed.
"We are pleased with today's ruling because it upholds our breakthrough inventions which made erythropoietin available to the millions of patients around the world who rely on this important therapy. Meaningful patent protection is fundamental to innovative research companies," said Kevin Sharer, Amgen's Chairman and Chief Executive Officer.
This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including Amgen's most recent Form 10-Q. Amgen conducts research in the biotechnology/pharmaceutical field where movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product.
Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. In addition, sales of Amgen's products are affected by reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers. These government regulations and reimbursement policies may affect the development, usage and pricing of Amgen's products.
In addition, while Amgen routinely obtains patents for products and technology, the protection offered by Amgen's patents and patent applications may be challenged, invalidated or circumvented by competitors.
Because forward-looking statements involve risks and uncertainties, actual results may differ materially from current results expected by Amgen. Amgen is providing this information as of January 19, 2001 and does not plan to update this information until its next press release and expressly disclaims any duty to update information contained in this press release.
Amgen is a global biotechnology company that discovers, develops, manufactures and markets cost-effective human therapeutics based on advances in cellular and molecular biology.
Contact: Amgen, Thousand Oaks
Jeff Richardson, 805/447-3227 (media)
Cary Rosansky, 805/447-4634 (investors)
gruß
proxi
